Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SIBY G AYALLOORE

Allopathic & Osteopathic Physicians Internal Medicine Advanced Heart Failure and Transplant Cardiology

NPI
1891985081
CMS profile
267277
Location
OPELOUSAS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,764.46

140 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,975.19 137
Travel and Lodging $781.37 2
Education $7.90 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SIBY G AYALLOORE

NPI 1891985081 · CMS profile ID 267277

Allopathic & Osteopathic Physicians / Internal Medicine / Advanced Heart Failure and Transplant Cardiology

OPELOUSAS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891985081?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SIBY G AYALLOORE, NPI 1891985081, CMS profile ID 267277. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891985081?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SIBY G AYALLOORE, NPI 1891985081, CMS profile ID 267277. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891985081?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SIBY G AYALLOORE, NPI 1891985081, CMS profile ID 267277, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1891985081?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

140 matching records · $3,764.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 140 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–140 of 140.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $9.7304/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709054963 CMS
Abbott Laboratories $10.0604/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664566209 CMS
E.R. Squibb & Sons, L.L.C. $11.6304/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651335087 CMS
Abbott Laboratories $3.6203/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664604497 CMS
Janssen Pharmaceuticals, Inc $19.8603/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658281507 CMS
Janssen Pharmaceuticals, Inc $4.2403/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658281505 CMS
Janssen Pharmaceuticals, Inc $4.0703/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658281503 CMS
PFIZER INC. $14.1203/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671906389 CMS
PFIZER INC. $0.8203/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672012725 CMS
PFIZER INC. $0.3403/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672042099 CMS
Novartis Pharmaceuticals Corporation $2.7903/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659158927 CMS
Boston Scientific Corporation $17.7703/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663006833 CMS
PFIZER INC. $16.1303/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671906623 CMS
Novartis Pharmaceuticals Corporation $17.6703/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659158892 CMS
ABIOMED $122.2703/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676722217 CMS
Janssen Pharmaceuticals, Inc $10.4703/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658281501 CMS
Merck Sharp & Dohme Corporation $48.0002/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695802479 CMS
Merck Sharp & Dohme Corporation $20.0002/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695802725 CMS
Merck Sharp & Dohme Corporation $30.0002/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695802729 CMS
Merck Sharp & Dohme Corporation $568.7302/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695802481 CMS
Merck Sharp & Dohme Corporation $91.0002/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695802483 CMS
Merck Sharp & Dohme Corporation $212.6402/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695802727 CMS
E.R. Squibb & Sons, L.L.C. $11.0302/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651335085 CMS
PFIZER INC. $19.5202/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671897393 CMS
Boston Scientific Corporation $16.0002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663006805 CMS
Janssen Pharmaceuticals, Inc $12.0202/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658281499 CMS
Janssen Pharmaceuticals, Inc $1.9702/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658281497 CMS
Novartis Pharmaceuticals Corporation $2.9702/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659158913 CMS
Novartis Pharmaceuticals Corporation $8.8702/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659158919 CMS
Gilead Sciences, Inc. $13.2002/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681475333 CMS
PFIZER INC. $18.3902/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671890987 CMS
PFIZER INC. $4.1002/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672030161 CMS
Gilead Sciences, Inc. $14.6902/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681475331 CMS
Novartis Pharmaceuticals Corporation $4.5202/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659158907 CMS
Janssen Pharmaceuticals, Inc $13.8001/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658281495 CMS
Boston Scientific Corporation $20.7601/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663006843 CMS
PFIZER INC. $16.7701/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671847431 CMS
Janssen Pharmaceuticals, Inc $11.6701/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658281493 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.9701/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700400029 CMS
PFIZER INC. $15.1701/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671847735 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,764.46 140
PY2020 $17,549.42 65
PY2021 $1,376.39 57
PY2022 $1,302.40 74
PY2023 $3,192.12 94
PY2024 $3,321.05 84
PY2025 $14,185.02 123

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $235,389.33 17
PY2024 Principal investigator $206,092.30 11
PY2023 Principal investigator $217,398.65 11
PY2022 Principal investigator $92,594.24 8
PY2021 Principal investigator $49,152.74 9
PY2020 Principal investigator $38,009.00 5
PY2019 Principal investigator $35,225.00 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $5,465.01 12/31/2025 Non-covered Recipient Entity
Cardiovascular Institute of the South
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1232920089
Principal investigator 1 Novartis Pharmaceuticals Corporation $86.68 12/31/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190307737
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,551.00 12/03/2025 Non-covered Recipient Entity
Cardiovascular Institute of the South (CIS) - Opelousas
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,598.00 12/03/2025 Non-covered Recipient Entity
Cardiovascular Institute of the South (CIS) - Opelousas
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508813
Principal investigator 1 Novartis Pharmaceuticals Corporation $20.16 11/15/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190307743
Principal investigator 1 Novartis Pharmaceuticals Corporation $112.58 10/30/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190307747
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,500.00 10/23/2025 Non-covered Recipient Entity
CIS CLINICAL RESEARCH CORP
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190309088
Principal investigator 1 Novartis Pharmaceuticals Corporation $133.67 10/09/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190307613
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,096.71 06/30/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190307615
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,770.70 03/27/2025 Non-covered Recipient Entity
CIS CLINICAL RESEARCH CORP
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190299183
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,120.00 03/25/2025 Non-covered Recipient Entity
CIS CLINICAL RESEARCH CORP
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190299190
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,986.42 02/28/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190307611
Principal investigator 1 Novartis Pharmaceuticals Corporation $46,612.85 02/04/2025 Non-covered Recipient Entity
CIS CLINICAL RESEARCH CORP
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190299194
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,065.70 01/30/2025 Non-covered Recipient Entity
CIS CLINICAL RESEARCH CORP
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190298830
Principal investigator 1 Novartis Pharmaceuticals Corporation $30,185.74 01/27/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190307741
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,424.39 01/15/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190307745
Principal investigator 1 Novartis Pharmaceuticals Corporation $74,659.72 01/13/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF THE SOUTH OPELOUSAS
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190307739